BenevolentAI Investor Presentation Deck
BEN-8744 results and progress to date
2020
Target
validation
2019
Novel, potent advanced lead molecule developed within 2 years
TARGET IDENTIFICATION
Novel target for UC
✓ Discovered using Benevolent
TargetID tools
✓ PDE10 has zero linkage to UC in
all available biomedical literature
✓ Experimentally validated in
ex-vivo UC colon samples from
patients refractory to SoC treatment
2021
Candidate
nomination
Preclinical
CHEMISTRY
Rapid and efficient lead
optimisation
✓ Molecular Design tools enabled
rapid and efficient lead optimisation
✓ Candidate nominated in Sep '21
Novel, potent, selective, peripherally
restricted PDE10. Inhibitor, with low
dose prediction
✓ Only 2 years from programme
initiation
2022
2023
Phase I clinical study
CLINICAL DEVELOPMENT
Developing responder and
progression endotypes
We will develop responder and
progression endotypes, adding
molecular descriptors
✓ These will inform our trial design,
patient selection and further target
identification in UC
✓ Augmenting a further loop of
iteration on an enriched graph
Benevolent 23View entire presentation